Navigation Links
Mylan Launches Generic Version of Viramune® Tablets
Date:5/23/2012

PITTSBURGH, May 23, 2012 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced that its subsidiary Mylan Pharmaceuticals Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Nevirapine Tablets USP, 200 mg. This product is the generic version of Boehringer Ingelheim's Viramune® and is indicated for combination antiretroviral (ARV) treatment of HIV-1 infection. (1)

Mylan CEO Heather Bresch said: "The launch of Nevirapine Tablets, 200 mg, in the U.S. further expands the reach of Mylan's global ARV portfolio. Currently, approximately one-third of HIV/AIDS patients in developing countries depend on a Mylan ARV product, and the company is committed to continue bringing affordable, high quality generic ARVs to market in the U.S."

Nevirapine Tablets, 200 mg, had U.S. sales of approximately $116.6 million for the 12 months ending March 31, 2012, according to IMS Health. Mylan is shipping its product immediately.

Currently, Mylan has 173 ANDAs pending FDA approval representing $92 billion in annual sales, according to IMS Health. Thirty-eight of these pending ANDAs are potential first-to-file opportunities, representing $25.5 billion in annual brand sales, for the 12 months ending Dec. 31, 2011, according to IMS Health.

Mylan is a global pharmaceutical company committed to setting new standards in health care. Working together around the world to provide 7 billion people access to high quality medicine, we innovate to satisfy unmet needs; make reliability and service a habit, do what's right, not what's easy and impact the future through passionate global leadership. We offer a growing portfolio of more than 1,100 generic pharmaceuticals and several brand medications. In addition, we offer a wide range of antiretroviral therapies, upon which approximately one-third of HIV/AIDS patients in developing countries depend. We also operate one of the largest active pharmaceutical ingredient manufacturers and currently market products in approximately 150 countries and territories. Our workforce of more than 18,000 people is dedicated to improving the customer experience and increasing pharmaceutical access to consumers around the world. But don't take our word for it. See for yourself. See inside. mylan.com  

(1) Both fatal and non-fatal liver damage and skin reactions have been reported in patients taking Nevirapine. Patients must be closely monitored during the first 18 weeks of therapy to detect these conditions.

 


'/>"/>
SOURCE Mylan Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Mylan Sponsors Drug Store News and Pharmacist Society to Provide a New Business Networking Platform for Pharmacy Schools and Students
2. Mylan Launches Generic Version of Plavix® Tablets
3. Mylan Launches Generic Lipitor® in Five European Countries
4. Mylan Reports Q1 2012 Adjusted Diluted EPS of $0.52, an 18% Increase Over Prior Year Quarter
5. Mylan and Pfizer Announce Epinephrine Auto-injector Settlement Agreement with Teva
6. Mylan Launches Generic Version of Zyprexa® Tablets
7. Mylan Launches First Generic Version of Lescol® Capsules
8. Mylan Schedules First Quarter 2012 Financial Results Conference Call and Live Webcast
9. Mylan One of First to Launch Generic Version of Boniva®
10. Mylan Canada Receives Health Canada Approval for Generic Version of Crestor®
11. Mylan Continues to Pursue Damages and Injunction Against Sunovions Brovana® in Ongoing Litigation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... Oct. 11, 2017  True Health, a leader ... its effort during National Breast Cancer Awareness month ... risks. Research ... calculated that more than 10 million American women ... in BRCA1 or BRCA2 and have not had testing. ...
(Date:10/7/2017)... IRVING, Texas , Oct. 6, 2017   ... industry with more than $100 billion in purchasing power, ... industry news and information. The Newsroom is ... chain and industry trends, infographics, expert bios, news releases, ... Besides having access to a wealth of resources at ...
(Date:10/4/2017)... LAWRENCE, Mass. , Oct. 4, 2017 /PRNewswire/ ... developer of single-use, self-contained, illuminating medical devices, today ... National Health Surveillance Agency (or Agência Nacional ... ®. The first single-use, cordless surgical retractor with ... ONETRAC provides optimal access, illumination and exposure of ...
Breaking Medicine Technology:
(Date:10/13/2017)... OBISPO, Calif. (PRWEB) , ... October 13, 2017 , ... ... or dementia. However, many long-term care insurance companies have a waiver for care if ... the 90-day elimination period, when the family pays for care, is often waived, so ...
(Date:10/13/2017)... ... October 13, 2017 , ... Talented host, actor Rob ... sciatica in a new episode of "Success Files," which is an award-winning educational ... and investigates each subject in-depth with passion and integrity. , Sciatica occurs when ...
(Date:10/12/2017)... ... October 12, 2017 , ... CitiDent and ... apnea using cutting-edge Oventus O2Vent technology. As many as 18 million Americans ... frequent cessation in breathing. Oral appliances can offer significant relief to about 75 ...
(Date:10/12/2017)... ... October 12, 2017 , ... Asante, a nationally recognized health ... expanded their existing home health joint venture through an agreement, effective October 1, ... joint venture home health company with Asante, delivering clinically integrated care, for the ...
(Date:10/12/2017)... Chapel, FL (PRWEB) , ... October 12, 2017 , ... ... is holding a treadmill relay – Miles by Moonlight to raise money for the ... donating $300 or more. , Teams will work together to keep their treadmills ...
Breaking Medicine News(10 mins):